To amend title XI of the Social Security Act to adjust which engineered cyclic peptides are qualifying single source drugs for purposes of the Drug Price Negotiation Program.
Summary
HR8857 is an early-stage bill that would exempt engineered cyclic peptides from Medicare drug price negotiation. It has minimal near-term market impact due to its procedural status and lack of specific drug identification. No funding is authorized.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR8857 is in the earliest legislative stage with low momentum.
- 2.No funding is authorized; the bill is a regulatory exemption.
- 3.JNJ and LLY are potential beneficiaries but the impact is speculative.
Market Implications
The bill has negligible near-term market implications. If it advances, it could modestly benefit pharmaceutical companies with cyclic peptide drugs by shielding them from Medicare negotiation. However, the lack of specificity and early legislative stage mean no actionable signal for retail investors now.
Full Analysis
-
On May 15, 2026, Rep. Morelle (D-NY) introduced HR8857, which amends the Social Security Act to adjust which engineered cyclic peptides qualify as single source drugs under the Drug Price Negotiation Program. The bill was referred to both the Energy and Commerce and Ways and Means Committees. It is in the earliest legislative stage with only 4 actions (introduction and referral).
-
The bill does not authorize or appropriate any funding. It is a regulatory change that would exempt certain drugs from Medicare price negotiation, thereby preserving their market pricing. The exact drugs affected are not specified, making revenue impact estimates impossible.
-
Potential beneficiaries are pharmaceutical companies with engineered cyclic peptide drugs in their portfolios. JNJ and LLY are the largest publicly traded companies with significant cyclic peptide-based therapies. However, the bill is too vague to determine which specific products are affected, and the legislative path is long.
-
No real market data is provided for stock prices. The competitive landscape for cyclic peptide drugs includes both large pharma and smaller biotechs, but the bill's early stage limits actionable conclusions.
-
The bill must pass both committees, the House, the Senate, and be signed by the President. With only 3 cosponsors and a junior sponsor, passage probability is low in the current Congress. No companion bill exists in the Senate.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Same as above — amends the definition of 'qualifying single source drug' to exclude engineered cyclic peptides from Medicare price negotiation.
Who must act
Centers for Medicare & Medicaid Services (CMS) — must adjust the list of drugs eligible for negotiation.
What happens
If enacted, specific engineered cyclic peptide drugs would be exempt from Medicare price negotiation, preserving their market pricing.
Stock impact
LLY's portfolio includes cyclic peptide-based drugs (e.g., certain diabetes and oncology therapies). Exemption from negotiation protects revenue from these products, though the exact drugs are not specified.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
ANGEL DESIGN BUILD CONSTRUCTION LLC: $12.4M Department of Veterans Affairs Contract
HELP Copays Act
A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Centers for Medicare & Medicaid Services of the Department of Health and Human Services relating to "Medicare Program; Implementation of Prior Authorization for Select Services for the Wasteful and Inappropriate Services Reduction (WISeR) Model".
To amend the Employee Retirement Income Security Act of 1974, title XXVII of the Public Health Service Act, and the Internal Revenue Code of 1986 to require health insurance coverage of drugs indicated for the treatment of autoimmune diseases and certain blood disorders.
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Wildlife Health Coordination and Zoonotic Disease Prevention Act of 2026
INSULIN Act of 2026
Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Continuing to Protect the Meaning and Value of American Citizenship
This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.
Ending Birth Tourism
This executive order directs the Secretaries of State and Homeland Security to prevent foreign nationals from entering the U.S. on nonimmigrant visas for the purpose of giving birth (birth tourism), including revoking visas, barring entry, and taking action against facilitators. It defines birth tourism as entry via nonimmigrant visa for childbirth and allows humanitarian or national interest exemptions.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →